Summary
CVS Health Corporation (CVS) filed an 8-K on February 7, 2024, to report its financial results for the fourth quarter and full year ended December 31, 2023. The key information for investors is contained within the press release furnished as Exhibit 99.1, which details the company's performance. Investors should review this press release for specific revenue, earnings, and other financial metrics that were announced on February 7, 2024. While this 8-K filing itself primarily serves to attach the press release, it signifies the official dissemination of the company's latest financial performance. The press release is the primary source of detail regarding operational and financial condition for the period. It is important for investors to note that the information furnished in this 8-K is not considered "filed" for purposes of Section 18 of the Exchange Act, meaning it does not carry the same legal implications as a fully filed document, though it does represent material information release.
Key Highlights
- 1CVS Health Corporation announced its fourth quarter and full year 2023 financial results via press release on February 7, 2024.
- 2The 8-K filing serves as the official submission of this press release to the SEC, making the results publicly available.
- 3Investors need to refer to Exhibit 99.1 (the press release) for detailed financial performance metrics.
- 4The filing covers the period ending December 31, 2023.
- 5The information provided is furnished, not filed, and therefore not subject to the liabilities of Section 18 of the Exchange Act.
- 6The 8-K also includes the cover page XBRL interactive data file for enhanced data analysis.